1. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
- Author
-
Ling Ao, Ting Lu, Yu Cao, Zhiwei Chen, Yuting Wang, Zisheng Li, Xingqian Ren, Pan Xu, Mingli Peng, Min Chen, Gaoli Zhang, Dejuan Xiang, Dachuan Cai, Peng Hu, Xiaofeng Shi, Dazhi Zhang, and Hong Ren
- Subjects
COVID-19 Vaccines ,SARS-CoV-2 ,Epidemiology ,Immunology ,COVID-19 ,HIV Infections ,General Medicine ,Antibodies, Viral ,Microbiology ,Immunogenicity, Vaccine ,Infectious Diseases ,Vaccines, Inactivated ,Seroepidemiologic Studies ,Immunoglobulin G ,Virology ,Drug Discovery ,Humans ,Parasitology - Abstract
It is important to know the safety and efficacy of vaccination in immunocompromised people living with HIV (PLWH), but currently, there is limited data on the inactivated SARS-CoV-2 vaccines’ safety and immune responses in PLWH. In this prospective observational study, 139 PLWH and 120 healthy controls were enrolled and monitored for 21–105 days after a two-dose vaccination. The safety, anti-receptor binding domain IgG (anti-RBD-IgG) and anti-spike-IgG responses, and RBD-specific memory B cell (MBC) responses were evaluated. The overall adverse events within seven days were reported in 12.9% (18/139) of PLWH and 13.3% (16/120) of healthy controls. No serious adverse events occurred in both groups. Overall, the seroprevalence of anti-RBD-IgG in PLWH was significantly decreased (87.1% vs. 99.2%; ppTrial registration:ClinicalTrials.gov identifier: NCT05043129..
- Published
- 2022